Publications by authors named "James Wassil"

Claim this Profile
E
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
James Wassil, Maggie Sisti, Jeff Fairman, Matthew Davis, Carlos Fierro

Lancet Infect Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of human vaccines on bacterial antimicrobial resistance. A review.
Kathrin U Jansen, William C Gruber, Raphael Simon, James Wassil, Annaliesa S Anderson

Environ Chem Lett· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
Jeff Fairman, Paresh Agarwal, Sandrine Barbanel, Christopher Behrens, Aym Berges, James Wassil

Vaccine· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
Terry Nolan, Miguel O'Ryan, James Wassil, Véronique Abitbol, Peter Dull

Vaccine· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
Duccio Medini, Maria Stella, James Wassil

Vaccine· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection.
E David McIntosh, Victor Carey, Daniela Toneatto, Peter Dull, James Wassil

Ther Adv Vaccines· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness has its place, but so does common sense.
Rino Rappuoli, James Wassil, Lars Bonefeld, John Porter

BMJ· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
James Wassil, Jasper Huels, Vasant Narasimhan

Vaccine· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.
Miguel O'Ryan, Jeffrey Stoddard, Daniela Toneatto, James Wassil, Peter M Dull

Drugs· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis